Anzurstobart (CC-95251, BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPalpha antibody that blocks the binding of CD47 to SIRPalpha. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research[1].
Molecular Weight:
(144.66 kDa)
Purity:
98.53
CAS Number:
[2543693-10-1]
Target:
CD47
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
